Abstract
* The Food and Drug Administration (FDA) has determined that drugs containing entacapone, used in the management of Parkinson's disease symptoms, does not increase the risk of cardiovascular events. * This announcement reverses an older FDA Drug Safety Communication in which the agency expressed concerns over possible cardiovascular events associated with use of the drug.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
